semaglutide and vision Long Island patients claim loss after taking Ozempic Wegovy GLP-1 drugs and vision loss:

Nie, and X

Benign naevi Circumscribed proliferations of melanocytes at the dermo-epidermal junction and/or in the dermis

At maintenance doses of 2.4 mg/week = 1.2 ml = 120 units

A larger randomized, placebo-controlled intervention trial (the SELECT study) in more than 35,000 middle-aged and selenium-replete men, randomized to receive selenium (in the form of selenomethionine, 200 g/day) and/or vitamin E supplementation, was halted because of concerns regarding an increased risk of type 2 diabetes mellitus with selenium and increased risk of prostate cancer with vitamin E (84, 85)

Coupled with Novo Nordisks top selling Ozempic and Wegovy (both semaglutide), GLP-1s have become part of mainstream discourses and even health policies due to their success in treating type-2 diabetes and weight loss